A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD

NCT02694770 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped corporate decision

Conditions

Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation

Interventions

BIOLOGICAL: Neihulizumab Treatment
BIOLOGICAL: Conventional Treatment

Sponsor

AbGenomics B.V Taiwan Branch